Shufen Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shufen Zhong has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Bing Sun
Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
3 shared publications Lin Zhu
Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, China
3 shared publicationsSiying Sun
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications- Yuying Huang
Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
3 shared publications - Bo Peng
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Guochao Shi
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
ILC2-intrinsic IL-33 amplifies ILC2 activation and allergic lung inflammation
Interleukin-33 (IL-33) from lung epithelial cells serves as a crucial alarmin to activate the lung-resident group 2 innate lymphoid cells (ILC2s) and then to initiate type 2 inflammation. However, whether IL-33 has an intrinsic role in the ILC2-driven lung inflammation remains unclear. In this study, we characterize the proteomic features of mouse lung ILC2s during activation and observe an increased expression of intrinsic IL-33 in activated ILC2s. The expression of intrinsic IL-33 in lung ILC2s can be induced by the co-stimulation of cysteinyl leukotrienes (CysLTs) and exogenous IL-33. Deletion of ILC2-intrinsic IL-33 attenuates lung inflammation by restraining ILC2 proliferation and cytokine production. Mechanistically, ILC2-intrinsic IL-33 promotes transcriptional activation of both inflammatory and proliferative signaling cascades. Additionally, ILC2-intrinsic IL-33 localizes in the nucleus and promotes the expression of Fosl2 and Nfatc1 through promoting their chromatin accessibility, leading to increased ILC2 proliferation and type 2 cytokine production. Further, we confirm that intrinsic IL-33 can be induced by co-stimulation of CysLTs and exogenous IL-33 in human ILC2s (hILC2s), which is positively related to enhanced hILC2 responses. Collectively, our findings implicate IL-33 as a nuclear factor and intrinsic amplifier of lung-resident ILC2s, operating in a positive feedback loop downstream of exogenous IL-33 and CysLTs co-stimulation to promote allergic lung inflammation.
- 16 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessILC2-intrinsic IL-33 amplifies ILC2 activation and allergic lung inflammation
Interleukin-33 (IL-33) from lung epithelial cells serves as a crucial alarmin to activate the lung-resident group 2 innate lymphoid cells (ILC2s) and then to initiate type 2 inflammation. However, whether IL-33 has an intrinsic role in the ILC2-driven lung inflammation remains unclear. In this study, we characterize the proteomic features of mouse lung ILC2s during activation and observe an increased expression of intrinsic IL-33 in activated ILC2s. The expression of intrinsic IL-33 in lung ILC2s can be induced by the co-stimulation of cysteinyl leukotrienes (CysLTs) and exogenous IL-33. Deletion of ILC2-intrinsic IL-33 attenuates lung inflammation by restraining ILC2 proliferation and cytokine production. Mechanistically, ILC2-intrinsic IL-33 promotes transcriptional activation of both inflammatory and proliferative signaling cascades. Additionally, ILC2-intrinsic IL-33 localizes in the nucleus and promotes the expression of Fosl2 and Nfatc1 through promoting their chromatin accessibility, leading to increased ILC2 proliferation and type 2 cytokine production. Further, we confirm that intrinsic IL-33 can be induced by co-stimulation of CysLTs and exogenous IL-33 in human ILC2s (hILC2s), which is positively related to enhanced hILC2 responses. Collectively, our findings implicate IL-33 as a nuclear factor and intrinsic amplifier of lung-resident ILC2s, operating in a positive feedback loop downstream of exogenous IL-33 and CysLTs co-stimulation to promote allergic lung inflammation.
- Open Access
- 16 October 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-15
Glutamate attenuates the ILC2 response and allergic airway inflammation via the kainate receptor GluK2
Group 2 innate lymphoid cells (ILC2s) play a critical role in initiating the type 2 immune response, particularly in allergic airway diseases. Although the effects of glutamate on the immune system have been reported previously, its role in modulating the function of ILC2s and lung inflammation remains unclear. In this study, we report that the glutamate levels increased in lung tissue following exposure to allergens. Consequently, glutamate was found to restrain ILC2 responses during lung inflammation in mice. Using Rag1 −/− mice, we demonstrated that the inhibitory effect of glutamate on type 2 inflammation was independent of T and B cells. Further ILC2 adoptive transfer experiments in Rag −/− Il2rg −/− mice confirmed that glutamate likely exerted its effects by directly targeting ILC2s. In vitro experiments revealed that glutamate suppressed ILC2 function through ionic kainate receptor signaling. Genetic deletion of the kainate receptor subunit GluK2 enhanced ILC2 responses and exacerbated type 2 lung inflammation. Mechanistically, transcriptome and metabolic analyses revealed that glutamate reduced oxidative metabolism in ILC2s, thereby limiting their activation. Consistently, in vivo administration of BPAM344—a positive allosteric modulator that potentiates GluK2 signaling—effectively suppressed allergen-induced type 2 inflammation. Notably, ILC2-specific GluK2 deletion markedly attenuated the anti-inflammatory effects of BPAM344, indicating that its protective effects depend on ILC2-intrinsic GluK2 signaling. These findings demonstrate a novel role for glutamate in restraining ILC2 function, as it plays a protective role in alleviating airway inflammation. We propose that GluK2 activation may offer a promising therapeutic strategy for treating ILC2-driven allergic asthma.
- 16 October 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-15
Open AccessGlutamate attenuates the ILC2 response and allergic airway inflammation via the kainate receptor GluK2
Group 2 innate lymphoid cells (ILC2s) play a critical role in initiating the type 2 immune response, particularly in allergic airway diseases. Although the effects of glutamate on the immune system have been reported previously, its role in modulating the function of ILC2s and lung inflammation remains unclear. In this study, we report that the glutamate levels increased in lung tissue following exposure to allergens. Consequently, glutamate was found to restrain ILC2 responses during lung inflammation in mice. Using Rag1 −/− mice, we demonstrated that the inhibitory effect of glutamate on type 2 inflammation was independent of T and B cells. Further ILC2 adoptive transfer experiments in Rag −/− Il2rg −/− mice confirmed that glutamate likely exerted its effects by directly targeting ILC2s. In vitro experiments revealed that glutamate suppressed ILC2 function through ionic kainate receptor signaling. Genetic deletion of the kainate receptor subunit GluK2 enhanced ILC2 responses and exacerbated type 2 lung inflammation. Mechanistically, transcriptome and metabolic analyses revealed that glutamate reduced oxidative metabolism in ILC2s, thereby limiting their activation. Consistently, in vivo administration of BPAM344—a positive allosteric modulator that potentiates GluK2 signaling—effectively suppressed allergen-induced type 2 inflammation. Notably, ILC2-specific GluK2 deletion markedly attenuated the anti-inflammatory effects of BPAM344, indicating that its protective effects depend on ILC2-intrinsic GluK2 signaling. These findings demonstrate a novel role for glutamate in restraining ILC2 function, as it plays a protective role in alleviating airway inflammation. We propose that GluK2 activation may offer a promising therapeutic strategy for treating ILC2-driven allergic asthma.
- 2 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-14
Acute stress alleviates type 2 lung inflammation by restricting ILC2s through corticosterone-glucocorticoid receptor signaling
The psychological state profoundly influences immune responses. While chronic stress is generally known to exacerbate inflammation, the impact of acute stress on inflammation has received far less attention. Here, we report that acute stress suppressed group 2 innate lymphoid cell (ILC2) responses, thereby alleviating type 2 lung inflammation. Restraint stress-induced acute stress activated the hypothalamic–pituitary–adrenal (HPA) axis and subsequently increased corticosterone levels. Corticosterone protected mice against lung inflammation by limiting ILC2 proliferation and type 2 cytokine production via the glucocorticoid receptor (GR). Adrenalectomy and genetic perturbation of the GR in ILC2s abolished acute stress-mediated immunosuppressive effects. Mechanistic studies revealed that corticosterone-GR signaling impaired ILC2 responses to microenvironmental factors by dampening downstream NF-κB and JAK-STAT signaling. Collectively, these findings reveal that acute stress alleviates ILC2-mediated lung inflammation through the neuroendocrine circuit and demonstrate the inhibitory role of endogenous corticosterone in ILC2 responses.
- 2 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-14
Acute stress alleviates type 2 lung inflammation by restricting ILC2s through corticosterone-glucocorticoid receptor signaling
The psychological state profoundly influences immune responses. While chronic stress is generally known to exacerbate inflammation, the impact of acute stress on inflammation has received far less attention. Here, we report that acute stress suppressed group 2 innate lymphoid cell (ILC2) responses, thereby alleviating type 2 lung inflammation. Restraint stress-induced acute stress activated the hypothalamic–pituitary–adrenal (HPA) axis and subsequently increased corticosterone levels. Corticosterone protected mice against lung inflammation by limiting ILC2 proliferation and type 2 cytokine production via the glucocorticoid receptor (GR). Adrenalectomy and genetic perturbation of the GR in ILC2s abolished acute stress-mediated immunosuppressive effects. Mechanistic studies revealed that corticosterone-GR signaling impaired ILC2 responses to microenvironmental factors by dampening downstream NF-κB and JAK-STAT signaling. Collectively, these findings reveal that acute stress alleviates ILC2-mediated lung inflammation through the neuroendocrine circuit and demonstrate the inhibitory role of endogenous corticosterone in ILC2 responses.